Company intelligence / Profile preview

Theradiag

Ownership: Private
Employees: ~61
Development stage: Commercial

Overview

Theradiag is a commercial-stage leader in theranostics and therapeutic drug monitoring for biotherapies. Its Lisa Tracker platform is CE-marked and widely adopted internationally for optimizing patient management with biologic therapies. The company has expanded its offerings into oncology drug monitoring. Clinical studies have demonstrated the value of their products in improving treatment outcomes.

Therapeutic areas: OncologyImmunology
Modalities: Diagnostic kitDevice
Industry: Protein Biomarker Diagnostics

Partnerships

Luminex Corporation (technology licensing/multiplex technology since 1999)Asuragen Inc. (molecular biology/onco-genetic products distribution partnership)Neovacs SA ("TRACKER" innovation plan partnership)Various international distributors (>70 countries)

Beyond the preview

Go deeper on Theradiag.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theradiag.

Explore the full profile